
Annual report 2024
added 03-21-2026
Genfit SA EPS Ratio 2011-2026 | GNFT
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Genfit SA
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 1.51 | -2.6 | -1.76 | -2.55 | -1.79 | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.51 | -2.6 | -1.44 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | ||
|
Lipocine
LPCN
|
-3.1 | $ 7.4 | 1.23 % | $ 39 M | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
Aileron Therapeutics
ALRN
|
-3.51 | - | 10.36 % | $ 9.8 M | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
-8.28 | $ 217.23 | -0.38 % | $ 5 B | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
2.1 | $ 19.47 | 1.25 % | $ 910 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
-5.9 | $ 8.28 | -1.84 % | $ 110 M | ||
|
Lexicon Pharmaceuticals
LXRX
|
-0.14 | $ 1.68 | 2.13 % | $ 610 M | ||
|
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-1.45 | $ 0.74 | 21.89 % | $ 8.48 M | ||
|
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-7.99 | - | -9.65 % | $ 45.9 M | ||
|
Exelixis
EXEL
|
2.88 | $ 41.51 | 0.23 % | $ 11.3 B | ||
|
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.36 | -3.21 % | $ 347 M | ||
|
Mesoblast Limited
MESO
|
-0.141 | $ 14.31 | 2.07 % | $ 9.29 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.46 | - | - | $ 7.46 M | ||
|
ChemoCentryx
CCXI
|
-1.89 | - | - | $ 3.74 B | ||
|
Genmab A/S
GMAB
|
34.4 | $ 25.73 | 0.19 % | $ 16.5 B | ||
|
Aytu BioScience
AYTU
|
-2.16 | $ 2.61 | -0.76 % | $ 16.4 M | ||
|
Atreca
BCEL
|
-2.52 | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
0.85 | - | -4.8 % | $ 255 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | ||
|
BeiGene, Ltd.
BGNE
|
0.2 | - | 0.49 % | $ 251 B | ||
|
Immatics N.V.
IMTX
|
-4.77 | $ 9.19 | -3.36 % | $ 578 M | ||
|
Bellerophon Therapeutics
BLPH
|
-2.08 | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-0.17 | $ 4.34 | -1.92 % | $ 832 M | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | ||
|
Ionis Pharmaceuticals
IONS
|
-1.41 | $ 69.55 | -1.75 % | $ 11.1 B | ||
|
Allakos
ALLK
|
-2.14 | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | ||
|
Longeveron
LGVN
|
-1.29 | $ 0.87 | -8.8 % | $ 15.3 B | ||
|
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M |